Jeffrey Tyner

Active 2002–2025

103
Papers
18,023
Citations
64
h-index
102
i10-index

Citations

Citations per year for Jeffrey Tyner1975: 1 citations1988: 1 citations2001: 1 citations2002: 2 citations2003: 2 citations2004: 7 citations2005: 7 citations2006: 19 citations2007: 38 citations2008: 48 citations2009: 69 citations2010: 60 citations2011: 91 citations2012: 124 citations2013: 126 citations2014: 131 citations2015: 114 citations2016: 92 citations2017: 129 citations2018: 135 citations2019: 505 citations2020: 600 citations2021: 617 citations2022: 732 citations2023: 608 citations2024: 1,136 citations2025: 465 citations2026: 15 citations1976–1987: no citations, so these years are not shown1989–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,485 citing papers, 29% of this breakdownChina: 946 citing papers, 11% of this breakdownUnited Kingdom: 539 citing papers, 6.3% of this breakdownGermany: 528 citing papers, 6.2% of this breakdownItaly: 479 citing papers, 5.6% of this breakdownFrance: 384 citing papers, 4.5% of this breakdownCanada: 255 citing papers, 3% of this breakdownAustralia: 232 citing papers, 2.7% of this breakdownSpain: 219 citing papers, 2.6% of this breakdownJapan: 215 citing papers, 2.5% of this breakdownNetherlands: 198 citing papers, 2.3% of this breakdownSwitzerland: 194 citing papers, 2.3% of this breakdown
0%29%Other 22%

Fields

  • Medicine64.4%
  • Biochemistry, Genetics and Molecular Biology25.2%
  • Immunology and Microbiology6.7%
  • Computer Science1.5%
  • Chemistry0.6%
  • Neuroscience0.4%
  • Other1.2%

Topics

  • Acute Myeloid Leukemia Research11.8%
  • Chronic Myeloid Leukemia Treatments4.9%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment4.4%
  • Chronic Lymphocytic Leukemia Research3.8%
  • Protein Degradation and Inhibitors2.8%
  • Acute Lymphoblastic Leukemia research2.6%
  • Other69.7%

Coauthors

All papers

Open in search
  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joop H. Jansen, Rashmi Kanagal‐Shamanna, Hagop M. Kantarjian, Christian P. Kratz, Xiaoqiu Li, Megan S. Lim, Keith R. Loeb, Sanam Loghavi, Andrea N. Marcogliese, Soheil Meshinchi, Phillip Michaels, Kikkeri N. Naresh, Yasodha Natkunam, Reza Nejati, German Ott, Eric Padron, Keyur P. Patel, Nikhil Patkar, Jennifer Picarsic, Uwe Platzbecker, Irene Roberts, Anna Schuh, William A. Sewell, Reiner Siebert, Prashant Tembhare, Jeffrey Tyner, Srđan Verstovšek, Wei Wang, Brent L. Wood, Wenbin Xiao, Cecilia C.S. Yeung, Andreas Hochhaus - Leukemia 2022 cited by 3,904

  2. Functional genomic landscape of acute myeloid leukaemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, Andy Kaempf, Jessica Leonard, Chenwei Lin, Selina Qiuying Liu, Pierrette Lo, Marc Loriaux, Samuel B. Luty, Tara A. Macey, Jason D. MacManiman, Jacqueline Martinez, Motomi Mori, Dylan Nelson, Ceilidh Nichols, Jill Peters, Justin Ramsdill, Angela Rofelty, Robert Schuff, Robert P. Searles, Erik Segerdell, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jake Wagner, Kevin Watanabe‐Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Denise C. Connolly, Michael W. Deininger, Leylah Drusbosky, Christopher S. Hourigan, Craig T. Jordan, Patricia Kropf, Tara L. Lin, Micaela Martínez, Bruno C. Medeiros, Rachel R. Pallapati, Daniel A. Pollyea, Ronan Swords, Justin M. Watts, Scott J. Weir, David L. Wiest, Ryan M. Winters, Shannon K. McWeeney, Brian Druker - Nature 2018 cited by 1,476

  3. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil K. Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyun-Jung Lee, Jessica Leonard, Chenwei Lin, Evan Lind, Selina Qiuying Liu, Pierrette Lo, Marc Loriaux, Samuel B. Luty, Julia E. Maxson, Tara A. Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Kyle A. Romine, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert P. Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela Martínez, Rachel R. Pallapati, Daniel A. Pollyea, Anthony D. Pomicter, Justin M. Watts, Scott J. Weir, Brian Druker, Shannon K. McWeeney, Jeffrey Tyner - Cancer Cell 2022 cited by 368

  4. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

    Authors: , , , , , , , , , , , , , , , - Cancer Discovery 2019 cited by 366

  5. AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2009 cited by 1,247

  6. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

    Authors: , , , , , , , , , - Nature Cancer 2020 cited by 203

  7. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , - Cell Reports 2017 cited by 270

  8. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2019 cited by 245

  9. An expanded universe of cancer targets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew L. Kung, Brent R. Stockwell, Jesse S. Boehm, Josh Dempster, Robert T. Manguso, Francisca Vázquez, Lee Cooper, Yuhong Du, Andrei A. Ivanov, Sagar Lonial, Carlos S. Moreno, Qiankun Niu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Matthew A. Reyna, Wei Zhou, Carla Grandori, Ilya Shmulevich, Elizabeth M. Swisher, Jitong Cai, Issac S. Chan, Matthew Dunworth, Yuchen Ge, Dan Georgess, Eloïse M. Grasset, Elodie Henriet, Hildur Knútsdóttir, Michael G. Lerner, Veena Padmanaban, Matthew C. Perrone, Yasir Suhail, Yohannes Tsehay, Manisha Warrier, Quin Morrow, Tamilla Nechiporuk, Nicola Long, Jennifer N. Saultz, Andy Kaempf, Jessica Minnier, Cristina E. Tognon, Stephen E. Kurtz, Anupriya Agarwal, Jordana F. Brown, Kevin Watanabe‐Smith, Tania Q. Vu, Thomas Jacob, Yunqi Yan, Bridget A. Robinson, Evan Lind, Yoko Kosaka, Emek Demir, Joseph Estabrook, Michael Grzadkowski, Olga Nikolova, Ken Chen, Ben Deneen, Han Liang, Michael C. Bassik, Asmita Bhattacharya, Kevin Brennan, Christina Curtis, Olivier Gevaert, Hanlee P. Ji, Kasper Karlsson, Kremena Karagyozova, Yuan‐Hung Lo, Katherine Liu, Michitaka Nakano, Anuja Sathe, Amber R. Smith and 25 more - Cell 2021 cited by 224

  10. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian Druker, Elie Traer - Cancer Cell 2021 cited by 147

  11. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , - Gut 2016 cited by 235

  12. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 92

  13. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 151

  14. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2008 cited by 524

  15. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gareth J. Morgan, Ola Landgren, Francesco Maura - Blood 2023 cited by 37

  16. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

    Authors: , , , , , , , , , , , , , - Blood 2010 cited by 718

  17. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Radimerski, Arend von Stackelberg, Cornelia Eckert, Jeffrey Tyner, Péter Horváth, Beat Bornhäuser, Jean‐Pierre Bourquin - Blood 2017 cited by 260

  18. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development

    Authors: , , , , , , , , , , , , , - Nature Cell Biology 2015 cited by 137

  19. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 109

  20. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 563

  21. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells

    Authors: , , , , , , , , , , , , , , , , - Blood 2018 cited by 108

  22. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 93

  23. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ricky W. Johnstone, Eric T. Gangl, Martin Wild, Michael Zinda, J. Paul Secrist, Barry R. Davies, Stephen E. Fawell, Francis D. Gibbons - Clinical Cancer Research 2020 cited by 69

  24. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

    Authors: , , , , , , , , , - Cancer Research 2016 cited by 165